A multiplex panel can promise dozens of answers from one small sample. Those proteins may occupy very different concentration ranges. Dilution that rescues an abundant chemokine can push a scarce cytokine below quantification. Choose a workable sample dilution at which the analytes of interest remain quantifiable together.
This guide compares Meso Scale Discovery electrochemiluminescence, Luminex xMAP bead assays, conventional ELISA, Ella microfluidic immunoassays and bead-based Simoa. Olink proximity extension assays provide a separate option for broader profiling. Choose by analyte, matrix, concentration range and workflow. The exact kit and sample preparation determine how well a platform serves the study.
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Start with the proteins that must be measurable. BIOLOGICAL PRIORITIES | \nPanels differ in antibody pairs, standards, sample requirements and the concentrations they can quantify. A nominally shared cytokine can perform differently in different kits on the same detection platform. | \nPanel size is a capacity claim. It does not establish that every requested biomarker is quantifiable in unstimulated plasma, stimulated medium or a tissue extract. | \nRank essential and optional analytes before choosing a panel. Test representative samples at several dilutions. Compare the proportion of essential results inside the reportable range, their precision and dilution behavior. Add a separate assay when one essential analyte needs different conditions. Sources: M4, M11, M12. Practical interpretation and proposed qualification. | \n
The antibody pair still defines what is recognized. MEASUREMENT IDENTITY | \nThe capture and detection reagents determine which protein forms an immunoassay recognizes. Calibration maps their signal onto a reference material; it does not erase differences in epitopes, protein forms or matrix response. | \nStrong correlations across platforms can coexist with substantially different concentrations. Shared units of pg/mL do not prove that two assays measure interchangeable quantities. | \nKeep one qualified assay through a longitudinal study when possible. If changing methods, bridge paired aliquots spanning the relevant range and examine bias as well as correlation. Investigate discrepancies in the context of antibody specificity, calibration and sample treatment. Sources: M11, M12. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Choose MSD for an ECL panel that fits the sample and range. MESO SCALE DISCOVERY | \nMSD uses electrically stimulated labels near electrodes in a plate. U-PLEX supports configurable spot-based panels; V-PLEX provides established panels; S-PLEX adds an ultrasensitive assay workflow. | \nThese families have different protocols and performance. A strong S-PLEX result cannot be attributed automatically to every MSD kit. Detector range also does not define the validated concentration interval of each analyte. | \nMSD is a useful candidate for focused multiplex biomarker work, especially when a suitable validated panel is available. Compare the exact assay family, required sample dilution and fraction of quantifiable samples. Evaluate S-PLEX specifically when baseline concentrations challenge standard assays. Sources: M1, M2, M3, M12. Practical interpretation and proposed qualification. | \n
Choose Luminex for a compatible bead panel with useful coverage. XMAP | \nxMAP distinguishes encoded bead populations carrying different capture reagents and measures reporter signal for each population. MAGPIX supports up to 50 analytes; other xMAP instruments have different capacities. | \nInstrument bead identities are not a guarantee of a validated panel of that size. Kit supplier, antibody combinations, sample preparation and bead recovery all influence performance. | \nLuminex is a useful candidate when several essential markers share a well-qualified panel and dilution. Verify kit and instrument compatibility, per-analyte bead counts and recovery after washing. Compare exact kits rather than treating every xMAP assay as the same analytical product. Sources: M4, M5. Practical interpretation and proposed qualification. | \n
Choose Ella when a focused panel and automated processing fit. MICROFLUIDIC IMMUNOASSAYS | \nElla Simple Plex performs immunoassays in cartridges. Singleplex and 2–4-analyte multianalyte formats use triplicate measurements; 5–8-analyte multiplex formats use duplicate measurements with two capture specificities per channel. | \nCartridge formats differ. Claims about separate channels and triplicates should not be transferred to every format. Internal replicate measurements share the original sample preparation. | \nElla is attractive for repeated, focused biomarker measurements when available cartridges cover the targets. Match capacity, sample volume and replicate structure to the exact cartridge. Technical replicates can reveal measurement variation but do not substitute for independent biological samples or separate preparation replicates. Sources: M6. Practical interpretation and proposed qualification. | \n
Choose bead-based Simoa when the low end limits the study. ULTRASENSITIVE DETECTION | \nBead-based Simoa isolates immunocomplex-bearing beads in tiny wells. Confining enzymatic product makes low occupancy detectable. This differs from Quanterix planar SP-X assays, despite shared Simoa branding on some materials. | \nGreater detection sensitivity does not solve antibody specificity, preanalytical variation or interference. Performance for a single-analyte kit cannot be assumed for all multiplexed versions. | \nConsider bead-based Simoa when biologically important baseline samples fall below quantification elsewhere. Evaluate precision and background near those concentrations using the intended matrix. Identify the actual bead or planar platform when reading comparative studies; they should not be merged into one performance claim. Sources: M7, M12. Practical interpretation and proposed qualification. | \n
Choose ELISA when one or a few established measurements suffice. CONVENTIONAL SINGLEPLEX | \nA conventional sandwich ELISA captures an analyte, removes unbound material and detects bound antibody-associated enzyme activity. It can use mature assay reagents and familiar laboratory workflows. | \nMultiple singleplex assays consume separate aliquots and repeated setup. Washing, timing, curve fitting and the antibody pair still need qualification. Familiarity does not establish superiority or inferiority. | \nELISA can be an efficient choice for focused confirmation, a small study or a marker with a particularly good established kit. Compare required sample volume, hands-on work and repeat frequency with multiplex options. A well-qualified singleplex result may be all the study needs. Sources: M1, M4. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Dilution changes the quantification limit in the original sample. SAMPLE CONCENTRATION | \nSuppose a qualified method measures diluted samples down to 0.5 pg/mL. A separate 100-fold predilution makes the corresponding original-sample limit 50 pg/mL. An original sample at 5 pg/mL becomes 0.05 pg/mL after that dilution. | \nThis calculation assumes recovery and a limit expressed for the diluted sample. Some kit reports already correct for their prescribed dilution; applying the same factor twice gives the wrong answer. | \nRecord the concentration basis and every dilution explicitly. Translate the validated assay interval back to the original specimen before ordering the study. A nominally more sensitive assay may lose its practical advantage if it requires substantially greater sample dilution. Sources: M4. Constructed arithmetic example; limits are illustrative, not product specifications. | \n
Group analytes by compatible dilution as well as biology. PANEL DESIGN | \nMSD offers a U-PLEX high-dilution panel for relatively abundant proteins. This reflects a general multiplex constraint: analytes must share tolerable concentrations and matrix conditions in the same reaction. | \nA broad detector range helps, but cannot rescue every incompatible calibration interval or matrix effect. The most abundant protein and the scarcest cytokine may need separate preparation. | \nPlot expected original-sample concentrations against dilution-adjusted working intervals. Split the panel when no common dilution preserves the essential targets. Two smaller panels that produce usable results can be more economical than one large panel followed by extensive repeats. Sources: M9, M4. Practical interpretation and proposed qualification. | \n
Physical separation reduces some interactions, not all of them. CROSSTALK AND SPECIFICITY | \nMSD separates capture spots, xMAP distinguishes bead identities, and selected Ella formats separate assays into channels. These arrangements solve different spatial and recognition problems. | \nAntibody cross-reactivity, shared-solution interference and optical leakage are distinct mechanisms. Better optical isolation cannot make a cross-reactive antibody specific; subtracting background cannot identify the wrongly captured protein. | \nFor a custom panel, challenge single analytes against the full detection mixture and test mixtures against single detection reagents where practical. Prefer designs that prevent unwanted interactions or stray light, then measure what remains. Normalization cannot replace specificity testing or recover photon information lost to contamination. Sources: M4, M6. Mechanistic distinction and proposed controls; no cross-platform optical ranking. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Spike recovery and endogenous parallelism answer different questions. MATRIX QUALIFICATION | \nSpike recovery tests what happens to added reference material in a matrix. Dilutional parallelism asks whether endogenous sample response tracks the calibration behavior across dilution. | \nRecombinant material may differ from endogenous protein in complex formation or epitope accessibility. Good spike recovery therefore does not guarantee that endogenous concentrations remain stable after dilution correction. | \nUse both checks where the matrix and endogenous range permit them. Investigate dilution-dependent recovery before accepting sample values. Predefine acceptance criteria appropriate to the intended decision rather than copying one percentage range into every assay. Sources: M4, M12. Practical interpretation and proposed qualification. | \n
A fitted concentration needs a defensible reportable interval. QUANTIFICATION | \nImmunoassays commonly use nonlinear calibration. Detection above blank, reliable quantification and the highest calibration point are different analytical concepts. | \nSoftware can return a number below the qualified low end or beyond the high end. A smooth fitted curve does not establish acceptable recovery or precision throughout that interval. | \nQualify the low and high ends with suitable controls and replicate samples. Distinguish below detection, detected below quantification and above range in the exported data. Use dilution and repeat rules established before the biological groups are compared. Sources: M4, M11. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Preanalytical variation can exceed the effect being studied. SPECIMEN HANDLING | \nCollection matrix, storage, thawing, centrifugation and dilution become part of the measurement workflow. Published comparisons use defined handling procedures and cannot establish equivalence for every alternative specimen preparation. | \nChanging serum to plasma, tube type or freeze-thaw history can alter interpretation. Normalizing plate signals cannot reverse a concentration change that occurred before the assay began. | \nStandardize collection and processing, retain an aliquot history and distribute biological groups across batches. Use pooled or otherwise appropriate bridge controls. Keep the incubation and reading temperatures specified by the selected kit; do not impose one universal room-temperature protocol on every platform. Sources: M4, M11. Practical interpretation and proposed qualification. | \n
Missing low results are not zero concentrations. CENSORED DATA | \nSome baseline cytokines can fall below quantification even on sensitive platforms. McKinski and colleagues found analyte-dependent coverage when comparing MSD S-PLEX and V-PLEX, Olink Target 48 and Quanterix SP-X. | \nReplacing every low result with zero, or with an arbitrary fixed fraction of a limit, can change group comparisons. A platform switch can change missingness without any biological change. | \nReport the quantifiable fraction by analyte and group. Decide with the analysis team how to handle censored values before comparing treatments. If a central endpoint is mostly unquantifiable, change the assay or the study question before committing the remaining samples. Sources: M12. Practical interpretation and proposed qualification. | \n
A bright signal can still be outside the useful chemical range. HIGH CONCENTRATIONS | \nSandwich binding can become reagent-limited, and very high analyte concentrations can produce nonmonotonic responses in susceptible assay designs. Detector saturation is a separate possible limit. | \nA generous instrument dynamic range does not prevent an antigen-excess hook. Conversely, dilution can improve matrix behavior as well as bring concentration into range. | \nTest highly positive specimens through a dilution series and check corrected recovery. Establish whether a kit has characterized high-dose behavior for the target. A repeated, lower result should prompt investigation rather than automatic acceptance as proof of a low sample concentration. Sources: M4, A12. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Broad profiling is useful when the biomarker list is still open. PROXIMITY EXTENSION | \nOlink PEA couples antibody recognition to DNA-based detection. Broad profiling products commonly report NPX, a relative log2-scale measure; some targeted products provide calibrated concentrations. | \nRelative expression units are not automatically convertible to pg/mL. An increase of one NPX unit describes a twofold change on that assay scale, not a universal conversion between different proteins. | \nChoose broad profiling for discovery across many candidate markers. Move decisive findings into a suitably qualified targeted assay when concentration, longitudinal comparability or a specific biological threshold matters. Identify the actual Olink product and output units rather than generalizing from the brand. Sources: M8. Practical interpretation and proposed qualification. | \n
Automation is most valuable when it removes your recurring bottleneck. WORKFLOW FIT | \nCartridge automation, multiplex plates and bead panels distribute preparation, washing and analysis differently. Their usefulness depends on sample arrival, staffing and available equipment. | \nInstrument read time excludes thawing, dilutions, standard preparation, incubation, washing, reruns and data review. A cartridge with unused capacity may still save labor; a larger batch may favor plates. | \nTime a representative day, including awkward samples and repeats. Compare small urgent batches with planned study plates. Choose the workflow that delivers accepted results on the required schedule, and price those results rather than nominal tests or instrument capacity. Sources: M6, M11. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Calibration sensitivity did not predict every plasma result. PUBLISHED COMPARISON | \nGunther and colleagues compared a MILLIPLEX/Luminex assay with three MSD kits in 62 plasma samples. MSD had lower calibration-based LLoQs for 14 of 16 shared cytokines, yet several endogenous cytokines were more often unquantifiable with MSD. | \nThe study involved specified kits, dilution and incubation conditions. Its operational definition of LLoQ used the greater of LoD and the lowest measurable standard; this is not a universal contemporary quantification criterion. | \nUse the result to design a pilot, not to declare a permanent platform winner. Require evidence from the intended specimen and analyte. Use endogenous specimens to establish how much of the intended biology the assay can quantify. Sources: M11. Primary study finding with its stated analytical limits. | \n
Compare candidates with paired samples and matched decisions. SELECTION PILOT | \nA useful pilot includes low, typical and high endogenous samples, relevant matrix variation and the essential analytes. Assays can follow their own qualified protocols while sharing the same aliquot source. | \nForcing identical dilution or incubation can disadvantage one method artificially. Comparing only recombinant standards avoids many of the problems that will appear in study samples. | \nPredefine pass criteria for quantifiable fraction, precision, dilution recovery, required volume and batch stability. Inspect paired concentration differences as well as correlations. Retain method-specific limits so that apparently discordant results can be understood rather than averaged together. Sources: M4, M11, M12. Practical interpretation and proposed qualification. | \n
Count accepted answers when estimating cost. STUDY ECONOMICS | \nNominal panel size and kit price omit out-of-range samples, repeats, confirmatory tests, calibrators and unused capacity. A scarce specimen can be the most expensive component. | \nA lower price per advertised analyte can become a higher price per interpretable result. Neither the broadest panel nor the smallest detection limit is automatically the economical choice. | \nBuild a small worksheet from the pilot: sample volume consumed, essential analytes reported, repeat rate, staff time and total consumables. Preserve enough specimen for confirmation. Use those figures to choose the panel and reserve the necessary confirmation volume. Sources: M4, M11. Practical costing framework; no prices or procurement ranking assumed. | \n
Row-level references identify manufacturer guidance and primary studies; practical recommendations and constructed examples are labelled separately. Performance belongs to the specified assay, sample and conditions. Validate the selected workflow in the intended biological material before committing a screen or study.
M1 MSD electrochemiluminescence technology
M2 MSD U-PLEX platform highlights
M3 MSD S-PLEX ultrasensitive biomarker development study 2020
M4 Luminex xMAP Cookbook fifth edition
M6 Bio-Techne Simple Plex assay formats
M8 Olink NPX frequently asked questions
M9 MSD U-PLEX high dilution panel 1 human
M11 Gunther et al 2020 Bead fluorescence versus planar ECL in human plasma
M12 McKinski et al 2025 Comparison of highly sensitive multiplex immunoassays
A12 Revvity explanation of the Alpha assay hook effect
", "body_text": "A multiplex panel can promise dozens of answers from one small sample. Those proteins may occupy very different concentration ranges. Dilution that rescues an abundant chemokine can push a scarce cytokine below quantification. Choose a workable sample dilution at which the analytes of interest remain quantifiable together.\n\nThis guide compares Meso Scale Discovery electrochemiluminescence, Luminex xMAP bead assays, conventional ELISA, Ella microfluidic immunoassays and bead-based Simoa. Olink proximity extension assays provide a separate option for broader profiling. Choose by analyte, matrix, concentration range and workflow. The exact kit and sample preparation determine how well a platform serves the study.\n\nHeadlinesChoosing MSD Luminex and alternative biomarker assays — HeadlinesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nStart with the proteins that must be measurable.BIOLOGICAL PRIORITIES | \nPanels differ in antibody pairs, standards, sample requirements and the concentrations they can quantify. A nominally shared cytokine can perform differently in different kits on the same detection platform. | \nPanel size is a capacity claim. It does not establish that every requested biomarker is quantifiable in unstimulated plasma, stimulated medium or a tissue extract. | \nRank essential and optional analytes before choosing a panel. Test representative samples at several dilutions. Compare the proportion of essential results inside the reportable range, their precision and dilution behavior. Add a separate assay when one essential analyte needs different conditions.Sources: M4, M11, M12. Practical interpretation and proposed qualification. | \n\n\nThe antibody pair still defines what is recognized.MEASUREMENT IDENTITY | \nThe capture and detection reagents determine which protein forms an immunoassay recognizes. Calibration maps their signal onto a reference material; it does not erase differences in epitopes, protein forms or matrix response. | \nStrong correlations across platforms can coexist with substantially different concentrations. Shared units of pg/mL do not prove that two assays measure interchangeable quantities. | \nKeep one qualified assay through a longitudinal study when possible. If changing methods, bridge paired aliquots spanning the relevant range and examine bias as well as correlation. Investigate discrepancies in the context of antibody specificity, calibration and sample treatment.Sources: M11, M12. Practical interpretation and proposed qualification. | \n\n\n\nSpecificationsChoosing MSD Luminex and alternative biomarker assays — SpecificationsThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nChoose MSD for an ECL panel that fits the sample and range.MESO SCALE DISCOVERY | \nMSD uses electrically stimulated labels near electrodes in a plate. U-PLEX supports configurable spot-based panels; V-PLEX provides established panels; S-PLEX adds an ultrasensitive assay workflow. | \nThese families have different protocols and performance. A strong S-PLEX result cannot be attributed automatically to every MSD kit. Detector range also does not define the validated concentration interval of each analyte. | \nMSD is a useful candidate for focused multiplex biomarker work, especially when a suitable validated panel is available. Compare the exact assay family, required sample dilution and fraction of quantifiable samples. Evaluate S-PLEX specifically when baseline concentrations challenge standard assays.Sources: M1, M2, M3, M12. Practical interpretation and proposed qualification. | \n\n\nChoose Luminex for a compatible bead panel with useful coverage.XMAP | \nxMAP distinguishes encoded bead populations carrying different capture reagents and measures reporter signal for each population. MAGPIX supports up to 50 analytes; other xMAP instruments have different capacities. | \nInstrument bead identities are not a guarantee of a validated panel of that size. Kit supplier, antibody combinations, sample preparation and bead recovery all influence performance. | \nLuminex is a useful candidate when several essential markers share a well-qualified panel and dilution. Verify kit and instrument compatibility, per-analyte bead counts and recovery after washing. Compare exact kits rather than treating every xMAP assay as the same analytical product.Sources: M4, M5. Practical interpretation and proposed qualification. | \n\n\nChoose Ella when a focused panel and automated processing fit.MICROFLUIDIC IMMUNOASSAYS | \nElla Simple Plex performs immunoassays in cartridges. Singleplex and 2–4-analyte multianalyte formats use triplicate measurements; 5–8-analyte multiplex formats use duplicate measurements with two capture specificities per channel. | \nCartridge formats differ. Claims about separate channels and triplicates should not be transferred to every format. Internal replicate measurements share the original sample preparation. | \nElla is attractive for repeated, focused biomarker measurements when available cartridges cover the targets. Match capacity, sample volume and replicate structure to the exact cartridge. Technical replicates can reveal measurement variation but do not substitute for independent biological samples or separate preparation replicates.Sources: M6. Practical interpretation and proposed qualification. | \n\n\nChoose bead-based Simoa when the low end limits the study.ULTRASENSITIVE DETECTION | \nBead-based Simoa isolates immunocomplex-bearing beads in tiny wells. Confining enzymatic product makes low occupancy detectable. This differs from Quanterix planar SP-X assays, despite shared Simoa branding on some materials. | \nGreater detection sensitivity does not solve antibody specificity, preanalytical variation or interference. Performance for a single-analyte kit cannot be assumed for all multiplexed versions. | \nConsider bead-based Simoa when biologically important baseline samples fall below quantification elsewhere. Evaluate precision and background near those concentrations using the intended matrix. Identify the actual bead or planar platform when reading comparative studies; they should not be merged into one performance claim.Sources: M7, M12. Practical interpretation and proposed qualification. | \n\n\nChoose ELISA when one or a few established measurements suffice.CONVENTIONAL SINGLEPLEX | \nA conventional sandwich ELISA captures an analyte, removes unbound material and detects bound antibody-associated enzyme activity. It can use mature assay reagents and familiar laboratory workflows. | \nMultiple singleplex assays consume separate aliquots and repeated setup. Washing, timing, curve fitting and the antibody pair still need qualification. Familiarity does not establish superiority or inferiority. | \nELISA can be an efficient choice for focused confirmation, a small study or a marker with a particularly good established kit. Compare required sample volume, hands-on work and repeat frequency with multiplex options. A well-qualified singleplex result may be all the study needs.Sources: M1, M4. Practical interpretation and proposed qualification. | \n\n\n\nFeaturesChoosing MSD Luminex and alternative biomarker assays — FeaturesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nDilution changes the quantification limit in the original sample.SAMPLE CONCENTRATION | \nSuppose a qualified method measures diluted samples down to 0.5 pg/mL. A separate 100-fold predilution makes the corresponding original-sample limit 50 pg/mL. An original sample at 5 pg/mL becomes 0.05 pg/mL after that dilution. | \nThis calculation assumes recovery and a limit expressed for the diluted sample. Some kit reports already correct for their prescribed dilution; applying the same factor twice gives the wrong answer. | \nRecord the concentration basis and every dilution explicitly. Translate the validated assay interval back to the original specimen before ordering the study. A nominally more sensitive assay may lose its practical advantage if it requires substantially greater sample dilution.Sources: M4. Constructed arithmetic example; limits are illustrative, not product specifications. | \n\n\nGroup analytes by compatible dilution as well as biology.PANEL DESIGN | \nMSD offers a U-PLEX high-dilution panel for relatively abundant proteins. This reflects a general multiplex constraint: analytes must share tolerable concentrations and matrix conditions in the same reaction. | \nA broad detector range helps, but cannot rescue every incompatible calibration interval or matrix effect. The most abundant protein and the scarcest cytokine may need separate preparation. | \nPlot expected original-sample concentrations against dilution-adjusted working intervals. Split the panel when no common dilution preserves the essential targets. Two smaller panels that produce usable results can be more economical than one large panel followed by extensive repeats.Sources: M9, M4. Practical interpretation and proposed qualification. | \n\n\nPhysical separation reduces some interactions, not all of them.CROSSTALK AND SPECIFICITY | \nMSD separates capture spots, xMAP distinguishes bead identities, and selected Ella formats separate assays into channels. These arrangements solve different spatial and recognition problems. | \nAntibody cross-reactivity, shared-solution interference and optical leakage are distinct mechanisms. Better optical isolation cannot make a cross-reactive antibody specific; subtracting background cannot identify the wrongly captured protein. | \nFor a custom panel, challenge single analytes against the full detection mixture and test mixtures against single detection reagents where practical. Prefer designs that prevent unwanted interactions or stray light, then measure what remains. Normalization cannot replace specificity testing or recover photon information lost to contamination.Sources: M4, M6. Mechanistic distinction and proposed controls; no cross-platform optical ranking. | \n\n\n\nCapabilitiesChoosing MSD Luminex and alternative biomarker assays — CapabilitiesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nSpike recovery and endogenous parallelism answer different questions.MATRIX QUALIFICATION | \nSpike recovery tests what happens to added reference material in a matrix. Dilutional parallelism asks whether endogenous sample response tracks the calibration behavior across dilution. | \nRecombinant material may differ from endogenous protein in complex formation or epitope accessibility. Good spike recovery therefore does not guarantee that endogenous concentrations remain stable after dilution correction. | \nUse both checks where the matrix and endogenous range permit them. Investigate dilution-dependent recovery before accepting sample values. Predefine acceptance criteria appropriate to the intended decision rather than copying one percentage range into every assay.Sources: M4, M12. Practical interpretation and proposed qualification. | \n\n\nA fitted concentration needs a defensible reportable interval.QUANTIFICATION | \nImmunoassays commonly use nonlinear calibration. Detection above blank, reliable quantification and the highest calibration point are different analytical concepts. | \nSoftware can return a number below the qualified low end or beyond the high end. A smooth fitted curve does not establish acceptable recovery or precision throughout that interval. | \nQualify the low and high ends with suitable controls and replicate samples. Distinguish below detection, detected below quantification and above range in the exported data. Use dilution and repeat rules established before the biological groups are compared.Sources: M4, M11. Practical interpretation and proposed qualification. | \n\n\n\nDownsidesChoosing MSD Luminex and alternative biomarker assays — DownsidesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nPreanalytical variation can exceed the effect being studied.SPECIMEN HANDLING | \nCollection matrix, storage, thawing, centrifugation and dilution become part of the measurement workflow. Published comparisons use defined handling procedures and cannot establish equivalence for every alternative specimen preparation. | \nChanging serum to plasma, tube type or freeze-thaw history can alter interpretation. Normalizing plate signals cannot reverse a concentration change that occurred before the assay began. | \nStandardize collection and processing, retain an aliquot history and distribute biological groups across batches. Use pooled or otherwise appropriate bridge controls. Keep the incubation and reading temperatures specified by the selected kit; do not impose one universal room-temperature protocol on every platform.Sources: M4, M11. Practical interpretation and proposed qualification. | \n\n\nMissing low results are not zero concentrations.CENSORED DATA | \nSome baseline cytokines can fall below quantification even on sensitive platforms. McKinski and colleagues found analyte-dependent coverage when comparing MSD S-PLEX and V-PLEX, Olink Target 48 and Quanterix SP-X. | \nReplacing every low result with zero, or with an arbitrary fixed fraction of a limit, can change group comparisons. A platform switch can change missingness without any biological change. | \nReport the quantifiable fraction by analyte and group. Decide with the analysis team how to handle censored values before comparing treatments. If a central endpoint is mostly unquantifiable, change the assay or the study question before committing the remaining samples.Sources: M12. Practical interpretation and proposed qualification. | \n\n\nA bright signal can still be outside the useful chemical range.HIGH CONCENTRATIONS | \nSandwich binding can become reagent-limited, and very high analyte concentrations can produce nonmonotonic responses in susceptible assay designs. Detector saturation is a separate possible limit. | \nA generous instrument dynamic range does not prevent an antigen-excess hook. Conversely, dilution can improve matrix behavior as well as bring concentration into range. | \nTest highly positive specimens through a dilution series and check corrected recovery. Establish whether a kit has characterized high-dose behavior for the target. A repeated, lower result should prompt investigation rather than automatic acceptance as proof of a low sample concentration.Sources: M4, A12. Practical interpretation and proposed qualification. | \n\n\n\nAdvantagesChoosing MSD Luminex and alternative biomarker assays — AdvantagesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nBroad profiling is useful when the biomarker list is still open.PROXIMITY EXTENSION | \nOlink PEA couples antibody recognition to DNA-based detection. Broad profiling products commonly report NPX, a relative log2-scale measure; some targeted products provide calibrated concentrations. | \nRelative expression units are not automatically convertible to pg/mL. An increase of one NPX unit describes a twofold change on that assay scale, not a universal conversion between different proteins. | \nChoose broad profiling for discovery across many candidate markers. Move decisive findings into a suitably qualified targeted assay when concentration, longitudinal comparability or a specific biological threshold matters. Identify the actual Olink product and output units rather than generalizing from the brand.Sources: M8. Practical interpretation and proposed qualification. | \n\n\nAutomation is most valuable when it removes your recurring bottleneck.WORKFLOW FIT | \nCartridge automation, multiplex plates and bead panels distribute preparation, washing and analysis differently. Their usefulness depends on sample arrival, staffing and available equipment. | \nInstrument read time excludes thawing, dilutions, standard preparation, incubation, washing, reruns and data review. A cartridge with unused capacity may still save labor; a larger batch may favor plates. | \nTime a representative day, including awkward samples and repeats. Compare small urgent batches with planned study plates. Choose the workflow that delivers accepted results on the required schedule, and price those results rather than nominal tests or instrument capacity.Sources: M6, M11. Practical interpretation and proposed qualification. | \n\n\n\nNotable DetailsChoosing MSD Luminex and alternative biomarker assays — Notable DetailsThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nCalibration sensitivity did not predict every plasma result.PUBLISHED COMPARISON | \nGunther and colleagues compared a MILLIPLEX/Luminex assay with three MSD kits in 62 plasma samples. MSD had lower calibration-based LLoQs for 14 of 16 shared cytokines, yet several endogenous cytokines were more often unquantifiable with MSD. | \nThe study involved specified kits, dilution and incubation conditions. Its operational definition of LLoQ used the greater of LoD and the lowest measurable standard; this is not a universal contemporary quantification criterion. | \nUse the result to design a pilot, not to declare a permanent platform winner. Require evidence from the intended specimen and analyte. Use endogenous specimens to establish how much of the intended biology the assay can quantify.Sources: M11. Primary study finding with its stated analytical limits. | \n\n\nCompare candidates with paired samples and matched decisions.SELECTION PILOT | \nA useful pilot includes low, typical and high endogenous samples, relevant matrix variation and the essential analytes. Assays can follow their own qualified protocols while sharing the same aliquot source. | \nForcing identical dilution or incubation can disadvantage one method artificially. Comparing only recombinant standards avoids many of the problems that will appear in study samples. | \nPredefine pass criteria for quantifiable fraction, precision, dilution recovery, required volume and batch stability. Inspect paired concentration differences as well as correlations. Retain method-specific limits so that apparently discordant results can be understood rather than averaged together.Sources: M4, M11, M12. Practical interpretation and proposed qualification. | \n\n\nCount accepted answers when estimating cost.STUDY ECONOMICS | \nNominal panel size and kit price omit out-of-range samples, repeats, confirmatory tests, calibrators and unused capacity. A scarce specimen can be the most expensive component. | \nA lower price per advertised analyte can become a higher price per interpretable result. Neither the broadest panel nor the smallest detection limit is automatically the economical choice. | \nBuild a small worksheet from the pilot: sample volume consumed, essential analytes reported, repeat rate, staff time and total consumables. Preserve enough specimen for confirmation. Use those figures to choose the panel and reserve the necessary confirmation volume.Sources: M4, M11. Practical costing framework; no prices or procurement ranking assumed. | \n\n\n\nAbout the sources\n\nRow-level references identify manufacturer guidance and primary studies; practical recommendations and constructed examples are labelled separately. Performance belongs to the specified assay, sample and conditions. Validate the selected workflow in the intended biological material before committing a screen or study.\n\nM1 MSD electrochemiluminescence technology\n\nM2 MSD U-PLEX platform highlights\n\nM3 MSD S-PLEX ultrasensitive biomarker development study 2020\n\nM4 Luminex xMAP Cookbook fifth edition\n\nM5 Diasorin MAGPIX system\n\nM6 Bio-Techne Simple Plex assay formats\n\nM7 Quanterix Simoa technology\n\nM8 Olink NPX frequently asked questions\n\nM9 MSD U-PLEX high dilution panel 1 human\n\nM11 Gunther et al 2020 Bead fluorescence versus planar ECL in human plasma\n\nM12 McKinski et al 2025 Comparison of highly sensitive multiplex immunoassays\n\nA12 Revvity explanation of the Alpha assay hook effect", "sections": [ { "id": "introduction", "heading": "Introduction", "blocks": [ { "type": "p", "text": "A multiplex panel can promise dozens of answers from one small sample. Those proteins may occupy very different concentration ranges. Dilution that rescues an abundant chemokine can push a scarce cytokine below quantification. Choose a workable sample dilution at which the analytes of interest remain quantifiable together.", "html": "A multiplex panel can promise dozens of answers from one small sample. Those proteins may occupy very different concentration ranges. Dilution that rescues an abundant chemokine can push a scarce cytokine below quantification. Choose a workable sample dilution at which the analytes of interest remain quantifiable together.
" }, { "type": "p", "text": "This guide compares Meso Scale Discovery electrochemiluminescence, Luminex xMAP bead assays, conventional ELISA, Ella microfluidic immunoassays and bead-based Simoa. Olink proximity extension assays provide a separate option for broader profiling. Choose by analyte, matrix, concentration range and workflow. The exact kit and sample preparation determine how well a platform serves the study.", "html": "This guide compares Meso Scale Discovery electrochemiluminescence, Luminex xMAP bead assays, conventional ELISA, Ella microfluidic immunoassays and bead-based Simoa. Olink proximity extension assays provide a separate option for broader profiling. Choose by analyte, matrix, concentration range and workflow. The exact kit and sample preparation determine how well a platform serves the study.
" }, { "type": "section", "text": "HeadlinesChoosing MSD Luminex and alternative biomarker assays — HeadlinesThe finding | Technology and product evidence | Trade-offs and controls | What it means | \n\nStart with the proteins that must be measurable.BIOLOGICAL PRIORITIES | \nPanels differ in antibody pairs, standards, sample requirements and the concentrations they can quantify. A nominally shared cytokine can perform differently in different kits on the same detection platform. | \nPanel size is a capacity claim. It does not establish that every requested biomarker is quantifiable in unstimulated plasma, stimulated medium or a tissue extract. | \nRank essential and optional analytes before choosing a panel. Test representative samples at several dilutions. Compare the proportion of essential results inside the reportable range, their precision and dilution behavior. Add a separate assay when one essential analyte needs different conditions.Sources: M4, M11, M12. Practical interpretation and proposed qualification. | \n\n\nThe antibody pair still defines what is recognized.MEASUREMENT IDENTITY | \nThe capture and detection reagents determine which protein forms an immunoassay recognizes. Calibration maps their signal onto a reference material; it does not erase differences in epitopes, protein forms or matrix response. | \nStrong correlations across platforms can coexist with substantially different concentrations. Shared units of pg/mL do not prove that two assays measure interchangeable quantities. | \nKeep one qualified assay through a longitudinal study when possible. If changing methods, bridge paired aliquots spanning the relevant range and examine bias as well as correlation. Investigate discrepancies in the context of antibody specificity, calibration and sample treatment.Sources: M11, M12. Practical interpretation and proposed qualification. | \n\n", "html": "| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Start with the proteins that must be measurable. BIOLOGICAL PRIORITIES | \nPanels differ in antibody pairs, standards, sample requirements and the concentrations they can quantify. A nominally shared cytokine can perform differently in different kits on the same detection platform. | \nPanel size is a capacity claim. It does not establish that every requested biomarker is quantifiable in unstimulated plasma, stimulated medium or a tissue extract. | \nRank essential and optional analytes before choosing a panel. Test representative samples at several dilutions. Compare the proportion of essential results inside the reportable range, their precision and dilution behavior. Add a separate assay when one essential analyte needs different conditions. Sources: M4, M11, M12. Practical interpretation and proposed qualification. | \n
The antibody pair still defines what is recognized. MEASUREMENT IDENTITY | \nThe capture and detection reagents determine which protein forms an immunoassay recognizes. Calibration maps their signal onto a reference material; it does not erase differences in epitopes, protein forms or matrix response. | \nStrong correlations across platforms can coexist with substantially different concentrations. Shared units of pg/mL do not prove that two assays measure interchangeable quantities. | \nKeep one qualified assay through a longitudinal study when possible. If changing methods, bridge paired aliquots spanning the relevant range and examine bias as well as correlation. Investigate discrepancies in the context of antibody specificity, calibration and sample treatment. Sources: M11, M12. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Choose MSD for an ECL panel that fits the sample and range. MESO SCALE DISCOVERY | \nMSD uses electrically stimulated labels near electrodes in a plate. U-PLEX supports configurable spot-based panels; V-PLEX provides established panels; S-PLEX adds an ultrasensitive assay workflow. | \nThese families have different protocols and performance. A strong S-PLEX result cannot be attributed automatically to every MSD kit. Detector range also does not define the validated concentration interval of each analyte. | \nMSD is a useful candidate for focused multiplex biomarker work, especially when a suitable validated panel is available. Compare the exact assay family, required sample dilution and fraction of quantifiable samples. Evaluate S-PLEX specifically when baseline concentrations challenge standard assays. Sources: M1, M2, M3, M12. Practical interpretation and proposed qualification. | \n
Choose Luminex for a compatible bead panel with useful coverage. XMAP | \nxMAP distinguishes encoded bead populations carrying different capture reagents and measures reporter signal for each population. MAGPIX supports up to 50 analytes; other xMAP instruments have different capacities. | \nInstrument bead identities are not a guarantee of a validated panel of that size. Kit supplier, antibody combinations, sample preparation and bead recovery all influence performance. | \nLuminex is a useful candidate when several essential markers share a well-qualified panel and dilution. Verify kit and instrument compatibility, per-analyte bead counts and recovery after washing. Compare exact kits rather than treating every xMAP assay as the same analytical product. Sources: M4, M5. Practical interpretation and proposed qualification. | \n
Choose Ella when a focused panel and automated processing fit. MICROFLUIDIC IMMUNOASSAYS | \nElla Simple Plex performs immunoassays in cartridges. Singleplex and 2–4-analyte multianalyte formats use triplicate measurements; 5–8-analyte multiplex formats use duplicate measurements with two capture specificities per channel. | \nCartridge formats differ. Claims about separate channels and triplicates should not be transferred to every format. Internal replicate measurements share the original sample preparation. | \nElla is attractive for repeated, focused biomarker measurements when available cartridges cover the targets. Match capacity, sample volume and replicate structure to the exact cartridge. Technical replicates can reveal measurement variation but do not substitute for independent biological samples or separate preparation replicates. Sources: M6. Practical interpretation and proposed qualification. | \n
Choose bead-based Simoa when the low end limits the study. ULTRASENSITIVE DETECTION | \nBead-based Simoa isolates immunocomplex-bearing beads in tiny wells. Confining enzymatic product makes low occupancy detectable. This differs from Quanterix planar SP-X assays, despite shared Simoa branding on some materials. | \nGreater detection sensitivity does not solve antibody specificity, preanalytical variation or interference. Performance for a single-analyte kit cannot be assumed for all multiplexed versions. | \nConsider bead-based Simoa when biologically important baseline samples fall below quantification elsewhere. Evaluate precision and background near those concentrations using the intended matrix. Identify the actual bead or planar platform when reading comparative studies; they should not be merged into one performance claim. Sources: M7, M12. Practical interpretation and proposed qualification. | \n
Choose ELISA when one or a few established measurements suffice. CONVENTIONAL SINGLEPLEX | \nA conventional sandwich ELISA captures an analyte, removes unbound material and detects bound antibody-associated enzyme activity. It can use mature assay reagents and familiar laboratory workflows. | \nMultiple singleplex assays consume separate aliquots and repeated setup. Washing, timing, curve fitting and the antibody pair still need qualification. Familiarity does not establish superiority or inferiority. | \nELISA can be an efficient choice for focused confirmation, a small study or a marker with a particularly good established kit. Compare required sample volume, hands-on work and repeat frequency with multiplex options. A well-qualified singleplex result may be all the study needs. Sources: M1, M4. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Dilution changes the quantification limit in the original sample. SAMPLE CONCENTRATION | \nSuppose a qualified method measures diluted samples down to 0.5 pg/mL. A separate 100-fold predilution makes the corresponding original-sample limit 50 pg/mL. An original sample at 5 pg/mL becomes 0.05 pg/mL after that dilution. | \nThis calculation assumes recovery and a limit expressed for the diluted sample. Some kit reports already correct for their prescribed dilution; applying the same factor twice gives the wrong answer. | \nRecord the concentration basis and every dilution explicitly. Translate the validated assay interval back to the original specimen before ordering the study. A nominally more sensitive assay may lose its practical advantage if it requires substantially greater sample dilution. Sources: M4. Constructed arithmetic example; limits are illustrative, not product specifications. | \n
Group analytes by compatible dilution as well as biology. PANEL DESIGN | \nMSD offers a U-PLEX high-dilution panel for relatively abundant proteins. This reflects a general multiplex constraint: analytes must share tolerable concentrations and matrix conditions in the same reaction. | \nA broad detector range helps, but cannot rescue every incompatible calibration interval or matrix effect. The most abundant protein and the scarcest cytokine may need separate preparation. | \nPlot expected original-sample concentrations against dilution-adjusted working intervals. Split the panel when no common dilution preserves the essential targets. Two smaller panels that produce usable results can be more economical than one large panel followed by extensive repeats. Sources: M9, M4. Practical interpretation and proposed qualification. | \n
Physical separation reduces some interactions, not all of them. CROSSTALK AND SPECIFICITY | \nMSD separates capture spots, xMAP distinguishes bead identities, and selected Ella formats separate assays into channels. These arrangements solve different spatial and recognition problems. | \nAntibody cross-reactivity, shared-solution interference and optical leakage are distinct mechanisms. Better optical isolation cannot make a cross-reactive antibody specific; subtracting background cannot identify the wrongly captured protein. | \nFor a custom panel, challenge single analytes against the full detection mixture and test mixtures against single detection reagents where practical. Prefer designs that prevent unwanted interactions or stray light, then measure what remains. Normalization cannot replace specificity testing or recover photon information lost to contamination. Sources: M4, M6. Mechanistic distinction and proposed controls; no cross-platform optical ranking. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Spike recovery and endogenous parallelism answer different questions. MATRIX QUALIFICATION | \nSpike recovery tests what happens to added reference material in a matrix. Dilutional parallelism asks whether endogenous sample response tracks the calibration behavior across dilution. | \nRecombinant material may differ from endogenous protein in complex formation or epitope accessibility. Good spike recovery therefore does not guarantee that endogenous concentrations remain stable after dilution correction. | \nUse both checks where the matrix and endogenous range permit them. Investigate dilution-dependent recovery before accepting sample values. Predefine acceptance criteria appropriate to the intended decision rather than copying one percentage range into every assay. Sources: M4, M12. Practical interpretation and proposed qualification. | \n
A fitted concentration needs a defensible reportable interval. QUANTIFICATION | \nImmunoassays commonly use nonlinear calibration. Detection above blank, reliable quantification and the highest calibration point are different analytical concepts. | \nSoftware can return a number below the qualified low end or beyond the high end. A smooth fitted curve does not establish acceptable recovery or precision throughout that interval. | \nQualify the low and high ends with suitable controls and replicate samples. Distinguish below detection, detected below quantification and above range in the exported data. Use dilution and repeat rules established before the biological groups are compared. Sources: M4, M11. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Preanalytical variation can exceed the effect being studied. SPECIMEN HANDLING | \nCollection matrix, storage, thawing, centrifugation and dilution become part of the measurement workflow. Published comparisons use defined handling procedures and cannot establish equivalence for every alternative specimen preparation. | \nChanging serum to plasma, tube type or freeze-thaw history can alter interpretation. Normalizing plate signals cannot reverse a concentration change that occurred before the assay began. | \nStandardize collection and processing, retain an aliquot history and distribute biological groups across batches. Use pooled or otherwise appropriate bridge controls. Keep the incubation and reading temperatures specified by the selected kit; do not impose one universal room-temperature protocol on every platform. Sources: M4, M11. Practical interpretation and proposed qualification. | \n
Missing low results are not zero concentrations. CENSORED DATA | \nSome baseline cytokines can fall below quantification even on sensitive platforms. McKinski and colleagues found analyte-dependent coverage when comparing MSD S-PLEX and V-PLEX, Olink Target 48 and Quanterix SP-X. | \nReplacing every low result with zero, or with an arbitrary fixed fraction of a limit, can change group comparisons. A platform switch can change missingness without any biological change. | \nReport the quantifiable fraction by analyte and group. Decide with the analysis team how to handle censored values before comparing treatments. If a central endpoint is mostly unquantifiable, change the assay or the study question before committing the remaining samples. Sources: M12. Practical interpretation and proposed qualification. | \n
A bright signal can still be outside the useful chemical range. HIGH CONCENTRATIONS | \nSandwich binding can become reagent-limited, and very high analyte concentrations can produce nonmonotonic responses in susceptible assay designs. Detector saturation is a separate possible limit. | \nA generous instrument dynamic range does not prevent an antigen-excess hook. Conversely, dilution can improve matrix behavior as well as bring concentration into range. | \nTest highly positive specimens through a dilution series and check corrected recovery. Establish whether a kit has characterized high-dose behavior for the target. A repeated, lower result should prompt investigation rather than automatic acceptance as proof of a low sample concentration. Sources: M4, A12. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Broad profiling is useful when the biomarker list is still open. PROXIMITY EXTENSION | \nOlink PEA couples antibody recognition to DNA-based detection. Broad profiling products commonly report NPX, a relative log2-scale measure; some targeted products provide calibrated concentrations. | \nRelative expression units are not automatically convertible to pg/mL. An increase of one NPX unit describes a twofold change on that assay scale, not a universal conversion between different proteins. | \nChoose broad profiling for discovery across many candidate markers. Move decisive findings into a suitably qualified targeted assay when concentration, longitudinal comparability or a specific biological threshold matters. Identify the actual Olink product and output units rather than generalizing from the brand. Sources: M8. Practical interpretation and proposed qualification. | \n
Automation is most valuable when it removes your recurring bottleneck. WORKFLOW FIT | \nCartridge automation, multiplex plates and bead panels distribute preparation, washing and analysis differently. Their usefulness depends on sample arrival, staffing and available equipment. | \nInstrument read time excludes thawing, dilutions, standard preparation, incubation, washing, reruns and data review. A cartridge with unused capacity may still save labor; a larger batch may favor plates. | \nTime a representative day, including awkward samples and repeats. Compare small urgent batches with planned study plates. Choose the workflow that delivers accepted results on the required schedule, and price those results rather than nominal tests or instrument capacity. Sources: M6, M11. Practical interpretation and proposed qualification. | \n
| The finding | Technology and product evidence | Trade-offs and controls | What it means |
|---|---|---|---|
Calibration sensitivity did not predict every plasma result. PUBLISHED COMPARISON | \nGunther and colleagues compared a MILLIPLEX/Luminex assay with three MSD kits in 62 plasma samples. MSD had lower calibration-based LLoQs for 14 of 16 shared cytokines, yet several endogenous cytokines were more often unquantifiable with MSD. | \nThe study involved specified kits, dilution and incubation conditions. Its operational definition of LLoQ used the greater of LoD and the lowest measurable standard; this is not a universal contemporary quantification criterion. | \nUse the result to design a pilot, not to declare a permanent platform winner. Require evidence from the intended specimen and analyte. Use endogenous specimens to establish how much of the intended biology the assay can quantify. Sources: M11. Primary study finding with its stated analytical limits. | \n
Compare candidates with paired samples and matched decisions. SELECTION PILOT | \nA useful pilot includes low, typical and high endogenous samples, relevant matrix variation and the essential analytes. Assays can follow their own qualified protocols while sharing the same aliquot source. | \nForcing identical dilution or incubation can disadvantage one method artificially. Comparing only recombinant standards avoids many of the problems that will appear in study samples. | \nPredefine pass criteria for quantifiable fraction, precision, dilution recovery, required volume and batch stability. Inspect paired concentration differences as well as correlations. Retain method-specific limits so that apparently discordant results can be understood rather than averaged together. Sources: M4, M11, M12. Practical interpretation and proposed qualification. | \n
Count accepted answers when estimating cost. STUDY ECONOMICS | \nNominal panel size and kit price omit out-of-range samples, repeats, confirmatory tests, calibrators and unused capacity. A scarce specimen can be the most expensive component. | \nA lower price per advertised analyte can become a higher price per interpretable result. Neither the broadest panel nor the smallest detection limit is automatically the economical choice. | \nBuild a small worksheet from the pilot: sample volume consumed, essential analytes reported, repeat rate, staff time and total consumables. Preserve enough specimen for confirmation. Use those figures to choose the panel and reserve the necessary confirmation volume. Sources: M4, M11. Practical costing framework; no prices or procurement ranking assumed. | \n
Row-level references identify manufacturer guidance and primary studies; practical recommendations and constructed examples are labelled separately. Performance belongs to the specified assay, sample and conditions. Validate the selected workflow in the intended biological material before committing a screen or study.
" }, { "type": "p", "text": "M1 MSD electrochemiluminescence technology", "html": "M1 MSD electrochemiluminescence technology
" }, { "type": "p", "text": "M2 MSD U-PLEX platform highlights", "html": "M2 MSD U-PLEX platform highlights
" }, { "type": "p", "text": "M3 MSD S-PLEX ultrasensitive biomarker development study 2020", "html": "M3 MSD S-PLEX ultrasensitive biomarker development study 2020
" }, { "type": "p", "text": "M4 Luminex xMAP Cookbook fifth edition", "html": "M4 Luminex xMAP Cookbook fifth edition
" }, { "type": "p", "text": "M5 Diasorin MAGPIX system", "html": "" }, { "type": "p", "text": "M6 Bio-Techne Simple Plex assay formats", "html": "M6 Bio-Techne Simple Plex assay formats
" }, { "type": "p", "text": "M7 Quanterix Simoa technology", "html": "" }, { "type": "p", "text": "M8 Olink NPX frequently asked questions", "html": "M8 Olink NPX frequently asked questions
" }, { "type": "p", "text": "M9 MSD U-PLEX high dilution panel 1 human", "html": "M9 MSD U-PLEX high dilution panel 1 human
" }, { "type": "p", "text": "M11 Gunther et al 2020 Bead fluorescence versus planar ECL in human plasma", "html": "M11 Gunther et al 2020 Bead fluorescence versus planar ECL in human plasma
" }, { "type": "p", "text": "M12 McKinski et al 2025 Comparison of highly sensitive multiplex immunoassays", "html": "M12 McKinski et al 2025 Comparison of highly sensitive multiplex immunoassays
" }, { "type": "p", "text": "A12 Revvity explanation of the Alpha assay hook effect", "html": "" } ] } ], "references": [ { "id": "ref-m1", "citation": "M1 MSD electrochemiluminescence technology", "urls": [ "https://www.mesoscale.com/en/technical_resources/our_technology/ecl" ] }, { "id": "ref-m2", "citation": "M2 MSD U-PLEX platform highlights", "urls": [ "https://www.mesoscale.com/~/media/files/product%20highlights/u-plex%20platform%20highlight.pdf" ] }, { "id": "ref-m3", "citation": "M3 MSD S-PLEX ultrasensitive biomarker development study 2020", "urls": [ "https://www.mesoscale.com/~/media/files/scientific%20poster/s-plex-development-ultrasensitive-biomarker-panel-2020.pdf" ] }, { "id": "ref-m4", "citation": "M4 Luminex xMAP Cookbook fifth edition", "urls": [ "https://f.hubspotusercontent30.net/hubfs/128032/Cookbook/BR402139.xMAPCookbook.Ed5.All.Sections.WR.pdf" ] }, { "id": "ref-m5", "citation": "M5 Diasorin MAGPIX system", "urls": [ "https://us.diasorin.com/en/luminex/products-and-services/tools/magpix-system" ] }, { "id": "ref-m6", "citation": "M6 Bio-Techne Simple Plex assay formats", "urls": [ "https://www.bio-techne.com/reagents/simple-plex-immunoassays" ] }, { "id": "ref-m7", "citation": "M7 Quanterix Simoa technology", "urls": [ "https://www.quanterix.com/simoa-technology/" ] }, { "id": "ref-m8", "citation": "M8 Olink NPX frequently asked questions", "urls": [ "https://olink.com/knowledge/faq?query=what+is+npx" ] }, { "id": "ref-m9", "citation": "M9 MSD U-PLEX high dilution panel 1 human", "urls": [ "https://www.mesoscale.com/en/products/u-plex-high-dilution-panel-1-human-k15751k/" ] }, { "id": "ref-m11", "citation": "M11 Gunther et al 2020 Bead fluorescence versus planar ECL in human plasma", "urls": [ "https://pmc.ncbi.nlm.nih.gov/articles/PMC7546899/" ] }, { "id": "ref-m12", "citation": "M12 McKinski et al 2025 Comparison of highly sensitive multiplex immunoassays", "urls": [ "https://pmc.ncbi.nlm.nih.gov/articles/PMC11749433/" ] }, { "id": "ref-a12", "citation": "A12 Revvity explanation of the Alpha assay hook effect", "urls": [ "https://www.revvity.com/ask/hook-effect" ] } ], "equations": [], "tables": [ { "caption": "Choosing MSD Luminex and alternative biomarker assays — Headlines", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Start with the proteins that must be measurable.BIOLOGICAL PRIORITIES", "Panels differ in antibody pairs, standards, sample requirements and the concentrations they can quantify. A nominally shared cytokine can perform differently in different kits on the same detection platform.", "Panel size is a capacity claim. It does not establish that every requested biomarker is quantifiable in unstimulated plasma, stimulated medium or a tissue extract.", "Rank essential and optional analytes before choosing a panel. Test representative samples at several dilutions. Compare the proportion of essential results inside the reportable range, their precision and dilution behavior. Add a separate assay when one essential analyte needs different conditions.Sources: M4, M11, M12. Practical interpretation and proposed qualification." ], [ "The antibody pair still defines what is recognized.MEASUREMENT IDENTITY", "The capture and detection reagents determine which protein forms an immunoassay recognizes. Calibration maps their signal onto a reference material; it does not erase differences in epitopes, protein forms or matrix response.", "Strong correlations across platforms can coexist with substantially different concentrations. Shared units of pg/mL do not prove that two assays measure interchangeable quantities.", "Keep one qualified assay through a longitudinal study when possible. If changing methods, bridge paired aliquots spanning the relevant range and examine bias as well as correlation. Investigate discrepancies in the context of antibody specificity, calibration and sample treatment.Sources: M11, M12. Practical interpretation and proposed qualification." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Choosing MSD Luminex and alternative biomarker assays — Specifications", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Choose MSD for an ECL panel that fits the sample and range.MESO SCALE DISCOVERY", "MSD uses electrically stimulated labels near electrodes in a plate. U-PLEX supports configurable spot-based panels; V-PLEX provides established panels; S-PLEX adds an ultrasensitive assay workflow.", "These families have different protocols and performance. A strong S-PLEX result cannot be attributed automatically to every MSD kit. Detector range also does not define the validated concentration interval of each analyte.", "MSD is a useful candidate for focused multiplex biomarker work, especially when a suitable validated panel is available. Compare the exact assay family, required sample dilution and fraction of quantifiable samples. Evaluate S-PLEX specifically when baseline concentrations challenge standard assays.Sources: M1, M2, M3, M12. Practical interpretation and proposed qualification." ], [ "Choose Luminex for a compatible bead panel with useful coverage.XMAP", "xMAP distinguishes encoded bead populations carrying different capture reagents and measures reporter signal for each population. MAGPIX supports up to 50 analytes; other xMAP instruments have different capacities.", "Instrument bead identities are not a guarantee of a validated panel of that size. Kit supplier, antibody combinations, sample preparation and bead recovery all influence performance.", "Luminex is a useful candidate when several essential markers share a well-qualified panel and dilution. Verify kit and instrument compatibility, per-analyte bead counts and recovery after washing. Compare exact kits rather than treating every xMAP assay as the same analytical product.Sources: M4, M5. Practical interpretation and proposed qualification." ], [ "Choose Ella when a focused panel and automated processing fit.MICROFLUIDIC IMMUNOASSAYS", "Ella Simple Plex performs immunoassays in cartridges. Singleplex and 2–4-analyte multianalyte formats use triplicate measurements; 5–8-analyte multiplex formats use duplicate measurements with two capture specificities per channel.", "Cartridge formats differ. Claims about separate channels and triplicates should not be transferred to every format. Internal replicate measurements share the original sample preparation.", "Ella is attractive for repeated, focused biomarker measurements when available cartridges cover the targets. Match capacity, sample volume and replicate structure to the exact cartridge. Technical replicates can reveal measurement variation but do not substitute for independent biological samples or separate preparation replicates.Sources: M6. Practical interpretation and proposed qualification." ], [ "Choose bead-based Simoa when the low end limits the study.ULTRASENSITIVE DETECTION", "Bead-based Simoa isolates immunocomplex-bearing beads in tiny wells. Confining enzymatic product makes low occupancy detectable. This differs from Quanterix planar SP-X assays, despite shared Simoa branding on some materials.", "Greater detection sensitivity does not solve antibody specificity, preanalytical variation or interference. Performance for a single-analyte kit cannot be assumed for all multiplexed versions.", "Consider bead-based Simoa when biologically important baseline samples fall below quantification elsewhere. Evaluate precision and background near those concentrations using the intended matrix. Identify the actual bead or planar platform when reading comparative studies; they should not be merged into one performance claim.Sources: M7, M12. Practical interpretation and proposed qualification." ], [ "Choose ELISA when one or a few established measurements suffice.CONVENTIONAL SINGLEPLEX", "A conventional sandwich ELISA captures an analyte, removes unbound material and detects bound antibody-associated enzyme activity. It can use mature assay reagents and familiar laboratory workflows.", "Multiple singleplex assays consume separate aliquots and repeated setup. Washing, timing, curve fitting and the antibody pair still need qualification. Familiarity does not establish superiority or inferiority.", "ELISA can be an efficient choice for focused confirmation, a small study or a marker with a particularly good established kit. Compare required sample volume, hands-on work and repeat frequency with multiplex options. A well-qualified singleplex result may be all the study needs.Sources: M1, M4. Practical interpretation and proposed qualification." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Choosing MSD Luminex and alternative biomarker assays — Features", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Dilution changes the quantification limit in the original sample.SAMPLE CONCENTRATION", "Suppose a qualified method measures diluted samples down to 0.5 pg/mL. A separate 100-fold predilution makes the corresponding original-sample limit 50 pg/mL. An original sample at 5 pg/mL becomes 0.05 pg/mL after that dilution.", "This calculation assumes recovery and a limit expressed for the diluted sample. Some kit reports already correct for their prescribed dilution; applying the same factor twice gives the wrong answer.", "Record the concentration basis and every dilution explicitly. Translate the validated assay interval back to the original specimen before ordering the study. A nominally more sensitive assay may lose its practical advantage if it requires substantially greater sample dilution.Sources: M4. Constructed arithmetic example; limits are illustrative, not product specifications." ], [ "Group analytes by compatible dilution as well as biology.PANEL DESIGN", "MSD offers a U-PLEX high-dilution panel for relatively abundant proteins. This reflects a general multiplex constraint: analytes must share tolerable concentrations and matrix conditions in the same reaction.", "A broad detector range helps, but cannot rescue every incompatible calibration interval or matrix effect. The most abundant protein and the scarcest cytokine may need separate preparation.", "Plot expected original-sample concentrations against dilution-adjusted working intervals. Split the panel when no common dilution preserves the essential targets. Two smaller panels that produce usable results can be more economical than one large panel followed by extensive repeats.Sources: M9, M4. Practical interpretation and proposed qualification." ], [ "Physical separation reduces some interactions, not all of them.CROSSTALK AND SPECIFICITY", "MSD separates capture spots, xMAP distinguishes bead identities, and selected Ella formats separate assays into channels. These arrangements solve different spatial and recognition problems.", "Antibody cross-reactivity, shared-solution interference and optical leakage are distinct mechanisms. Better optical isolation cannot make a cross-reactive antibody specific; subtracting background cannot identify the wrongly captured protein.", "For a custom panel, challenge single analytes against the full detection mixture and test mixtures against single detection reagents where practical. Prefer designs that prevent unwanted interactions or stray light, then measure what remains. Normalization cannot replace specificity testing or recover photon information lost to contamination.Sources: M4, M6. Mechanistic distinction and proposed controls; no cross-platform optical ranking." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Choosing MSD Luminex and alternative biomarker assays — Capabilities", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Spike recovery and endogenous parallelism answer different questions.MATRIX QUALIFICATION", "Spike recovery tests what happens to added reference material in a matrix. Dilutional parallelism asks whether endogenous sample response tracks the calibration behavior across dilution.", "Recombinant material may differ from endogenous protein in complex formation or epitope accessibility. Good spike recovery therefore does not guarantee that endogenous concentrations remain stable after dilution correction.", "Use both checks where the matrix and endogenous range permit them. Investigate dilution-dependent recovery before accepting sample values. Predefine acceptance criteria appropriate to the intended decision rather than copying one percentage range into every assay.Sources: M4, M12. Practical interpretation and proposed qualification." ], [ "A fitted concentration needs a defensible reportable interval.QUANTIFICATION", "Immunoassays commonly use nonlinear calibration. Detection above blank, reliable quantification and the highest calibration point are different analytical concepts.", "Software can return a number below the qualified low end or beyond the high end. A smooth fitted curve does not establish acceptable recovery or precision throughout that interval.", "Qualify the low and high ends with suitable controls and replicate samples. Distinguish below detection, detected below quantification and above range in the exported data. Use dilution and repeat rules established before the biological groups are compared.Sources: M4, M11. Practical interpretation and proposed qualification." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Choosing MSD Luminex and alternative biomarker assays — Downsides", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Preanalytical variation can exceed the effect being studied.SPECIMEN HANDLING", "Collection matrix, storage, thawing, centrifugation and dilution become part of the measurement workflow. Published comparisons use defined handling procedures and cannot establish equivalence for every alternative specimen preparation.", "Changing serum to plasma, tube type or freeze-thaw history can alter interpretation. Normalizing plate signals cannot reverse a concentration change that occurred before the assay began.", "Standardize collection and processing, retain an aliquot history and distribute biological groups across batches. Use pooled or otherwise appropriate bridge controls. Keep the incubation and reading temperatures specified by the selected kit; do not impose one universal room-temperature protocol on every platform.Sources: M4, M11. Practical interpretation and proposed qualification." ], [ "Missing low results are not zero concentrations.CENSORED DATA", "Some baseline cytokines can fall below quantification even on sensitive platforms. McKinski and colleagues found analyte-dependent coverage when comparing MSD S-PLEX and V-PLEX, Olink Target 48 and Quanterix SP-X.", "Replacing every low result with zero, or with an arbitrary fixed fraction of a limit, can change group comparisons. A platform switch can change missingness without any biological change.", "Report the quantifiable fraction by analyte and group. Decide with the analysis team how to handle censored values before comparing treatments. If a central endpoint is mostly unquantifiable, change the assay or the study question before committing the remaining samples.Sources: M12. Practical interpretation and proposed qualification." ], [ "A bright signal can still be outside the useful chemical range.HIGH CONCENTRATIONS", "Sandwich binding can become reagent-limited, and very high analyte concentrations can produce nonmonotonic responses in susceptible assay designs. Detector saturation is a separate possible limit.", "A generous instrument dynamic range does not prevent an antigen-excess hook. Conversely, dilution can improve matrix behavior as well as bring concentration into range.", "Test highly positive specimens through a dilution series and check corrected recovery. Establish whether a kit has characterized high-dose behavior for the target. A repeated, lower result should prompt investigation rather than automatic acceptance as proof of a low sample concentration.Sources: M4, A12. Practical interpretation and proposed qualification." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Choosing MSD Luminex and alternative biomarker assays — Advantages", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Broad profiling is useful when the biomarker list is still open.PROXIMITY EXTENSION", "Olink PEA couples antibody recognition to DNA-based detection. Broad profiling products commonly report NPX, a relative log2-scale measure; some targeted products provide calibrated concentrations.", "Relative expression units are not automatically convertible to pg/mL. An increase of one NPX unit describes a twofold change on that assay scale, not a universal conversion between different proteins.", "Choose broad profiling for discovery across many candidate markers. Move decisive findings into a suitably qualified targeted assay when concentration, longitudinal comparability or a specific biological threshold matters. Identify the actual Olink product and output units rather than generalizing from the brand.Sources: M8. Practical interpretation and proposed qualification." ], [ "Automation is most valuable when it removes your recurring bottleneck.WORKFLOW FIT", "Cartridge automation, multiplex plates and bead panels distribute preparation, washing and analysis differently. Their usefulness depends on sample arrival, staffing and available equipment.", "Instrument read time excludes thawing, dilutions, standard preparation, incubation, washing, reruns and data review. A cartridge with unused capacity may still save labor; a larger batch may favor plates.", "Time a representative day, including awkward samples and repeats. Compare small urgent batches with planned study plates. Choose the workflow that delivers accepted results on the required schedule, and price those results rather than nominal tests or instrument capacity.Sources: M6, M11. Practical interpretation and proposed qualification." ] ], "data_kind": "source comparison and stated illustrative calculations" }, { "caption": "Choosing MSD Luminex and alternative biomarker assays — Notable Details", "rows": [ [ "The finding", "Technology and product evidence", "Trade-offs and controls", "What it means" ], [ "Calibration sensitivity did not predict every plasma result.PUBLISHED COMPARISON", "Gunther and colleagues compared a MILLIPLEX/Luminex assay with three MSD kits in 62 plasma samples. MSD had lower calibration-based LLoQs for 14 of 16 shared cytokines, yet several endogenous cytokines were more often unquantifiable with MSD.", "The study involved specified kits, dilution and incubation conditions. Its operational definition of LLoQ used the greater of LoD and the lowest measurable standard; this is not a universal contemporary quantification criterion.", "Use the result to design a pilot, not to declare a permanent platform winner. Require evidence from the intended specimen and analyte. Use endogenous specimens to establish how much of the intended biology the assay can quantify.Sources: M11. Primary study finding with its stated analytical limits." ], [ "Compare candidates with paired samples and matched decisions.SELECTION PILOT", "A useful pilot includes low, typical and high endogenous samples, relevant matrix variation and the essential analytes. Assays can follow their own qualified protocols while sharing the same aliquot source.", "Forcing identical dilution or incubation can disadvantage one method artificially. Comparing only recombinant standards avoids many of the problems that will appear in study samples.", "Predefine pass criteria for quantifiable fraction, precision, dilution recovery, required volume and batch stability. Inspect paired concentration differences as well as correlations. Retain method-specific limits so that apparently discordant results can be understood rather than averaged together.Sources: M4, M11, M12. Practical interpretation and proposed qualification." ], [ "Count accepted answers when estimating cost.STUDY ECONOMICS", "Nominal panel size and kit price omit out-of-range samples, repeats, confirmatory tests, calibrators and unused capacity. A scarce specimen can be the most expensive component.", "A lower price per advertised analyte can become a higher price per interpretable result. Neither the broadest panel nor the smallest detection limit is automatically the economical choice.", "Build a small worksheet from the pilot: sample volume consumed, essential analytes reported, repeat rate, staff time and total consumables. Preserve enough specimen for confirmation. Use those figures to choose the panel and reserve the necessary confirmation volume.Sources: M4, M11. Practical costing framework; no prices or procurement ranking assumed." ] ], "data_kind": "source comparison and stated illustrative calculations" } ], "display_additions": {}, "content_sha256": "4c1c3909bb19155a55859dbb1bd2f512c21b96da2c0754190b97f5441d75d2af" }